Annamycin
Chemical compound
- none
- (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo- 6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9- (2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
- 92689-49-1 Y
- 115212
- 103088 Y
- SNU299M83Q
- D12844
- DTXSID901027238
- Interactive image
- O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@@](O)(C(=O)CO)C[C@@H]5O[C@@H]4O[C@H]([C@H](O)[C@@H](O)[C@H]4I)C
InChI
- InChI=1S/C26H25IO11/c1-9-19(30)24(35)18(27)25(37-9)38-13-7-26(36,14(29)8-28)6-12-15(13)23(34)17-16(22(12)33)20(31)10-4-2-3-5-11(10)21(17)32/h2-5,9,13,18-19,24-25,28,30,33-36H,6-8H2,1H3/t9-,13-,18+,19-,24-,25-,26-/m0/s1 Y
- Key:CIDNKDMVSINJCG-GKXONYSUSA-N Y
Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer.
Further reading
- Priebe W (1995). "Mechanism of action-governed design of anthracycline antibiotics: a "turn-off/turn-on" approach". Current Pharmaceutical Design. 1 (1): 51–68. doi:10.2174/1381612801666220524190711. S2CID 90406009.
- Trevino AV, Woynarowska BA, Herman TS, Priebe W, Woynarowski JM (November 2004). "Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues". Mol Cancer Ther. 3 (11): 1403–10. doi:10.1158/1535-7163.1403.3.11. PMID 15542779.
External links
- National Cancer Institute Definition of Annamycin
- v
- t
- e